This study enrolled 102 patients from different ethnic minorities who were diagnosed with hepatitis C (with positive serum anti-HCV) at the Second Hospital of Dalian Medical University, Anshan Central Hospital, and the Second People's Hospital of Fuxin City between November 2011 and November 2019. Investigators obtained informed consent before enrolling participants into this study. All patients met the diagnostic criteria of the Guidelines for the Prevention and Treatment of Hepatitis C, which was formulated by the Chinese Society of Hepatology and Society of Infectious Diseases.[7] The study was approved by the Research Ethics Committee of Dalian Medical University, Liaoning, China. All patients provided written informed consent.

注意:以上内容是从某篇研究文章中自动提取的,可能无法正确显示。



Q&A
请登录并在线提交您的问题
您的问题将发布在Bio-101网站上。我们会将您的问题发送给本研究方案的作者和具有相关研究经验的Bio-protocol成员。我们将通过您的Bio-protocol帐户绑定邮箱进行消息通知。